2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
12:00 p.m. - 01:30 p.m.
MCCNO - 278-282
Treatment Considerations, Combination Therapy, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Immunotherapy, Diseases, Lymphoid Malignancies, Lymphomas, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Research, Clinical Research, Clinical Trials
PAPER

167 Phase II investigator-initiated trial of epcoritamab-lenalidomide in treatment Naïve follicular lymphoma

Swetha Thiruvengadam, MD, Lu Chen, PhD2, Vi Lam, Graduate Student3, Xiaofan Zhao4, Avyakta Kallam, MBBS5, John Baird, MD6, Azra Borogovac, MD7, James Godfrey, MD8, Benjamin Heyman, MD9, Alex Francisco Herrera, MD10, Tycel Phillips, MD, FASCO11, Lara Rodriguez12, Katie Romero13, Neer Patel14, Eunice Canche15, Ashly Grafton16, Dina Hassan17, Diane Lynne Smith, PhD18, Steven T Rosen, MD19, Zheng Xia, PhD20, Alexey V. Danilov, MD, PhD21
1 City of Hope National Medical Center, Duarte, United States
2 City of Hope National Medical Center, Duarte, United States
3 City of Hope National Medical Center, Duarte, United States
4 Oregon Health & Science University, Portland, United States
5 City of Hope National Medical Center, Duarte, United States
6 City of Hope National Medical Center, Duarte, United States
7 City of Hope National Medical Center, Duarte, United States
8 City of Hope National Medical Center, Duarte, United States
9 City of Hope National Medical Center, Duarte, United States
10 City of Hope National Medical Center, Duarte, United States
11 City of Hope National Medical Center, Duarte, United States
12 City of Hope National Medical Center, Duarte, United States
13 City of Hope National Medical Center, Duarte, United States
14 City of Hope National Medical Center, Duarte, United States
15 City of Hope National Medical Center, Duarte, United States
16 City of Hope National Medical Center, Duarte, United States
17 City of Hope National Medical Center, Duarte, United States
18 City of Hope National Medical Center, Duarte, United States
19 City of Hope National Medical Center, Duarte, United States
20 Oregon Health & Science University, Portland, United States
21 City of Hope National Medical Center, Duarte, United States

Bispecific antibodies (BsAb) offer effective and safe chemotherapy-free, time-limited options for frontline follicular lymphoma (FL). Epcoritamab plus lenalidomide (E-len) and rituximab demonstrated high complete response rates (CRR) in the 1L and R/R settings. Yet rituximab is associated with increased risk of infections, infusion-related reactions, and costs, and it is unclear that dual targeting of CD20 with rituximab and BsAb is necessary. We present interim analysis results of a phase 2 single arm study () evaluating the efficacy and safety of E-len in frontline FL.

 

Adult patients (pts) with treatment naïve CD20+ histologically confirmed classic FL grade 1-3A needing systemic treatment by GELF criteria were eligible. Epcoritamab was dosed subcutaneously weekly in cycle (C) 1-3, with 3 step-up doses in C1, and every 4 weeks from C4. Len 20 mg was given orally on days 1-21 of a 28-day cycle. Pts continued treatment until unacceptable toxicity, disease progression or a total of 12 cycles, whichever occurred first. Response was assessed per Lugano 2014 criteria. Primary objective was CRR and secondary objectives included overall response rate (ORR), progression-free survival, duration of response, and safety. A Simon two stage Minimax design was used (N=25; H0 45%, HA 70%, power 80%, alpha level 0.043; stage 1= 12 pts).

 

Twenty-eight pts enrolled between 01/2024 and 10/2025. Median age was 60 (range, 35-80), 12 (43%) female, 7 (25%) Hispanics, 26 (93%) stage (III/IV), 18 (64%) FLIPI 3-5. Median number of cycles was 10 (range, 1-12). Twenty-two completed 12 cycles; 3 terminated within 1 cycle, and 3 were still on treatment. Five pts (18%) experienced cycle delay due to bradycardia (n=1), grade (G) 4 neutropenia (n=3), and PE/DVT (n=1). Two pts (7%) started a reduced dose of len due to renal dysfunction, and 16 pts (57%) required a dose reduction of len during study treatment for neutropenia (n=5), rash (n=5), fatigue (n=2), diarrhea (n=2), bradycardia (n=1), or combination (n=1).  Five pts (18%) required permanent discontinuation of len due to: G3 orbital angioedema and exfoliation (n=1), G3 rash (n=1), G3 venous PE/DVT (n=2), and insurance issue (n=1). One pt had C5-C12 len held due to fungal infection.

 

Twenty-eight pts were evaluable for toxicities. The most common any grade treatment-related adverse events (TrAEs) were cytokine release syndrome (CRS) in 21 (75%), maculopapular rash in 20 (71%), fatigue in 20 (71%), injection site reaction in 19 (68%), neutropenia in 18 (64%), constipation in 16 (57%), diarrhea in 14 ( 50%), anemia in 13 (46%), thrombocytopenia in 13 (43%), and fever in 13 (43%) pts. The most frequent G3-4 TrAEs were neutropenia in 13 (46%), maculopapular rash in 6 (21%), PE/DVT in 2 (7%), and lymphopenia in 2 (7%) pts. CRS was mostly low grade: 15 (54%) pts G1, 5 (18%) pt G2, and 1 (4%) pt G3. Infection was observed in 6 (21%) pts, all low grade. No ICANS or febrile neutropenia was observed.

 

Of the 28 pts, 3 received < 1 cycle due to MD decision (concern for transformation, G3 CRS after first dose, and non-compliance) and were deemed non-response evaluable and replaced. Twenty-five pts were evaluable for response; ORR was 100% and CRR was 96% (24/25). All responses (21 CRs and 4 PRs) were observed at time of first disease assessment at C4,  with 3 PRs converting to CR at C7 (n=2) or C10 (n=1). At a median follow-up of 17 months, no progression or death was noted (16mPFS = 100%).

 

We conducted RNA-Seq analysis of PBMCs from 8 responding pts obtained at baseline and after 3 and 6 cycles of therapy. We observed a decrease in B cells along with increase in CD4+ and CD8+ T cells subsets longitudinally. Gene set enrichment analysis revealed upregulation of MYC targets in CD8+ T cells, accompanied by downregulation of E2F and G2M checkpoint genes in CD4+ and CD8+ T cells. There was no increase in T-cell exhaustion markers. Additional analyses revealed treatment-associated enrichment of the naive/central-memory-like fitness features within the T-cell compartment, including TCF7/LEF1, IL7R/CCR7/LTB, and CD27/CD28-associated signals and treatment-associated myeloid/DC remodeling, including increased antigen-presentation and costimulatory programs.

 

E-Len is safe and effective for treatment-naïve FL pts, resulting in early and high CR rates. T-cell analysis demonstrated a favorable effect of E-Len on T-cell functionality over time. Longer follow-up will be needed to evaluate the durability of responses.

Swetha Thiruvengadam, MD: Innate Pharma SA - Honoraria; ADC Therapeutics - Research Funding; Genmab - Research Funding; Genentech - Research Funding; Innate Pharma SA - Consultancy (Includes expert testimony)